Experimental Depression Drug Fails Key Mid Stage Clinical Trial
A Promising Depression Drug Misses Its Main Goal An experimental depression drug being developed by Contineum Therapeutics in collaboration with Johnson & Johnson has failed to meet the primary efficacy goal of a Phase 2 clinical trial in adults with major depressive disorder. The drug, known as JNJ 5120 or PIPE 307, was being investigated […]







